Medtronic: A Smaller Company. A Stronger Investment? | EP027 cover art

Medtronic: A Smaller Company. A Stronger Investment? | EP027

Medtronic: A Smaller Company. A Stronger Investment? | EP027

Listen for free

View show details
Medtronic completed the MiniMed separation on 15 October 2026. Does a more focused company offer a stronger investment case? This conversation examines procedure growth, cash conversion and the evidence behind the dated model view.Research basis and the business after MiniMedResearch as of 21 October 2026. Medtronic plc ordinary shares: MDT.NYSE, USD, ISIN IE00BTN1Y115. Read the asset’s Medtronic Consensus research and twenty-quarter forecast for the underlying dated research. The released September labels are Buy at both 1Y and 5Y, including and excluding dividends, on the original USD 92.13 reference dated 18 September 2026. They are not a new rating computed at this episode’s reference price.The 14 October final exchange results specify 252,813,348 MiniMed shares exchanged for 55,032,401 Medtronic ordinary shares. Medtronic confirmed completion on 15 October. This was a split-off exchange by participating shareholders, not a cash sale or an automatic pro-rata distribution to every holder. Formally, a spin-off distributes subsidiary shares while a split-off exchanges parent shares; the conversational opening uses spins-off broadly for divestment, not as a technical definition of a cash sale. Medtronic no longer retains a MiniMed interest. Share retirement and removal of diabetes earnings must be assessed together with transition costs.The continuing device businesses span cardiovascular, neuroscience and surgical technology. Examples include Micra pacemakers, Evolut valves, Affera mapping and ablation, and Hugo robotic assistance. Clinical approval, payer coverage, installation and actual instrument use are different milestones.Four financial findingsThe financial checks use the FY2026 full-year results, first-quarter FY2027 release and quarterly SEC Form 10-Q for 31 July 2026. These consolidated periods precede the completed separation.* Earnings and sales: Q1 FY2027 revenue was USD 9.756 bn, up 13.7% reported and 13.7% on the company’s organic definition. The extra fiscal week contributed an estimated USD 570 m; the organic measure does not remove it. Subtracting that estimated benefit suggests roughly 7% underlying organic growth. The next normal-length quarters are a more useful test than extrapolating 13.7%.* Profitability: FY2026 GAAP operating profit was USD 6.467 bn with a 17.8% margin, essentially flat year over year. Q1 FY2027 GAAP operating profit was USD 1.764 bn and margin 18.1%; adjusted operating profit was USD 2.316 bn and margin 23.7%. Portfolio simplification and procedural mix offer scope for improvement, not a guaranteed margin jump.* Balance sheet: At 31 July 2026, cash USD 1.691 bn plus investments USD 7.128 bn totaled USD 8.819 bn. Current debt USD 2.536 bn plus long-term debt USD 25.617 bn totaled USD 28.153 bn. Goodwill USD 43.187 bn and other intangible assets USD 10.238 bn are substantial. These are dated pre-separation consolidated balances, not a post-split recast or an assurance of dividend safety.* Investment intensity: FY2026 property-and-equipment additions were USD 1.904 bn, or 5.2359% of USD 36.364 bn sales. The maintenance/growth split is unavailable. Research and acquisitions are additional uses of capital. The quarterly filing also reports approximately USD 700 m paid for the Cornerstone Robotics investment during Q2 FY2027. Judge returns on total investment, not factory capex alone.One cash bridge, with historical contextFY2026 operating cash USD 7.330 bn − property-and-equipment additions USD 1.904 bn = company-defined free cash flow USD 5.426 bn. Dividends used USD 3.639 bn; buybacks USD 1.035 bn and acquisitions net of cash acquired USD 0.406 bn were separate uses. FCF is a flow, not cash held at the balance-sheet date. A trailing calculation through Q1 FY2027 is USD 5.426 bn + USD 1.290 bn − USD 0.584 bn = USD 6.132 bn; it still includes diabetes and calendar effects, so it is not an unqualified post-separation run rate.The five-year chart uses comparable company-defined annual FCF from the FY2023 release and comparative cash-flow schedules and FY2026 comparative cash-flow schedules. All years below include the diabetes business; fiscal years are not calendar years.* Fiscal year: FY2022; Operating cash (USD bn): 7.346; PP&E additions (USD bn): 1.368; FCF = operating cash − PP&E (USD bn): 5.978* Fiscal year: FY2023; Operating cash (USD bn): 6.039; PP&E additions (USD bn): 1.459; FCF = operating cash − PP&E (USD bn): 4.580* Fiscal year: FY2024; Operating cash (USD bn): 6.787; PP&E additions (USD bn): 1.587; FCF = operating cash − PP&E (USD bn): 5.200* Fiscal year: FY2025; Operating cash (USD bn): 7.044; PP&E additions (USD bn): 1.859; FCF = operating cash − PP&E (USD bn): 5.185* Fiscal year: FY2026; Operating cash (USD bn): 7.330; PP&E additions (USD bn): 1.904; FCF = operating cash − PP&E (USD bn): 5.426Reference price, scenarios and dividend cashThe recording reference is USD 94.645: Alpaca IEX last available trade on 20 October 2026 at ...
adbl_web_anon_alc_button_suppression_t1
No reviews yet